Answers are grounded in this paper and cite their sources.
Background: Shushkakshipaka is one of the 76 Netrarogas described by Acharya Sushruta and is classified as a Sarvagata Sadhya Vyadhi caused mainly by vitiated Vata and Pitta. Its features Netrashushkata, Darunavartma, Paka, Toda, Bheda, Avila Darshana and Krichhra Unmilana–Nimilana closely resemble Dry Eye Disease (DED), whose prevalence in India is estimated at 29.25%. Lubricating eye gels are the mainstay of modern treatment, but frequent instillation may reduce patient compliance. Anjana, one of the seven Kriyakalpas, is indicated for Shushkakshipaka, and all ingredients of Manjishtadi Anjana are described as Chakshushya.Aim: To study the efficacy of Manjishtadi Anjana in Shushkakshipaka with special reference to Dry Eye Disease and to compare it with Mahaoushadhi Anjana.Materials and Methods: An open randomized controlled clinical study was conducted on 76 patients aged 18–55 years, allocated by simple random (lottery) method into two groups of 38 each. Group A (Trial) received Manjishtadi Anjana 4 Shalaka Matra (approx. 0.5 g) and Group B (Control) received Mahaoushadhi Anjana 1.5 Harenu Matra (approx. 5.8 mg), once daily in the morning for 7 days. Follow-ups were taken on day 7 (with medication) and day 15 (without medication). Five subjective parameters were graded 0–3, and Schirmer's test was the objective parameter. Data were analysed with the Wilcoxon signed rank test, Mann–Whitney U test, and paired and unpaired t-tests.Results: Both groups showed statistically highly significant improvement in all subjective parameters and in Schirmer's test (p < 0.001). Mean Schirmer's test value rose from 9.21 to 16.13 mm in the Trial group and from 9.58 to 16.42 mm in the Control group. Overall percentage effect was 73.73% in the Trial group and 73.09% in the Control group. No statistically significant difference was found between the groups for any parameter (p > 0.05).Conclusion: Manjishtadi Anjana is significantly effective in the management of Shushkakshipaka and is comparable in efficacy to Mahaoushadhi Anjana. No untoward effects were observed in either group.
No takes yet. Share an insight, caveat, or question.
Raju et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: